Project Grant R01CA318641
Award Date 7/23/26
Completion Date 6/30/31
Dollars Obligated $737K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $283,091 on September 2, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a career development project in implementation science for pediatric CAR-T cell therapy. The award funds Dr. Duffy's research to identify generalizable lessons for implementing chimeric antigen receptor T-cell programs across resource-constrained healthcare settings and to develop tools facilitating CAR-T program...
- The National Cancer Institute awarded St Jude Children's Research Hospital Inc. $423,188 on July 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project on compartmentalized branched-chain amino acid metabolism in myeloid leukemia. The award funds research investigating how BCAT1, a cytosolic enzyme catalyzing branched-chain amino acid metabolism, becomes aberrantly activated in acute myeloid leukemia and drives leukemogenesis through production of...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $738,666 on August 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer CD19 mimotopes for enhancing and repurposing CD19-CAR T cell therapy against hematological malignancies and solid tumors. The recipient will develop a high-affinity CD19 mimotope identified through yeast surface display screening to pair with existing CD19-CAR T products. The linear mimotope, a 10 amino acid peptide, is...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $263,656 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into novel mechanisms of acute myeloid leukemia (AML) resistance to chimeric antigen receptor T cell (CAR-T) therapy. The research aims to develop a detailed understanding of how altered STAT5 levels dictate poor outcomes for AML CAR-T therapies and to identify a combination therapy that selectively blocks AML...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $491,925 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to develop machine learning methods for estimating personal symptom networks in childhood cancer survivors. The project applies interpretable machine learning to estimate individual-level symptom networks that incorporate cancer therapy history, genetic profile, demographics, socioeconomic status, lifestyle factors, and...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $617,486 to ST Jude Children's Research Hospital Inc. on March 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The research investigates how chimeric transcription factors, specifically PAX3-FOXO1 and PAX7-FOXO1 fusion oncoproteins, suppress intrinsic innate immune responses in alveolar rhabdomyosarcoma (ARMS), an aggressive childhood soft...
- The National Cancer Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $706,866 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize FLT3-targeted and menin-modulated chimeric antigen receptor (CAR) T cell immunotherapies against KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) and prevent treatment-resistant relapse and lineage switch to acute myeloid leukemia. The recipient will develop best-in-class...
- The National Cancer Institute awarded St. Jude Children's Research Hospital Inc. $475,681 on June 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to explore CLK2 inhibition as a therapeutic target in rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma in children and young adults. Current treatment relies on multimodal therapies including chemotherapy, surgical resection, and radiotherapy, but five-year event-free survival for patients with metastasis at...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $647,502 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors targeting DDX19A as a novel anti-cancer therapeutic in Ewing sarcoma. The research examines DDX19A as a genomic dependency in Ewing sarcoma, an aggressive bone malignancy driven by the EWSR1:FLI1 fusion oncoprotein. Loss of DDX19A triggers marked global upregulation of transcription and chromatin...